Moreover, the genetic differences of pretreatment BCC and post-treatment cSCC are minor (3%) [27], and mutations associated with cSCC development (e.g., in effectors of the Hippo-YAP pathway and in MYCN) [28,29,30,31] have also been identified in BCC [17]. This evidence concerns the gene MYCN and skin basal cell carcinoma.